We currently have ongoing clinical trials evaluating our epilepsy product candidates: XEN1101 and XEN901. Please click on the identifier number below to view a summary of current and past studies as posted on ClinicalTrials.gov.
ClinicalTrials.gov Identifier NCT03796962: Phase 2b Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
ClinicalTrials.gov Identifier NCT03468725: Phase 1b Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101
ClinicalTrials.gov Identifier NCT03340220: Phase 1a Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN1101
ClinicalTrials.gov Identifier NCT03467100: Phase 1 Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901
Xenon is not currently recruiting patients for genetic or epidemiology studies. For more information, please email: email@example.com